Clinical trials: Steroid Resistant Acute Graft Versus Host Disease
Acute Graft-versus-host Disease
MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD
The purpose of this study is to compare the efficacy of CD25 monoclonal antibody and calcineurin inhibitors with or without mesenchymal stem cells (MSCs) in treating patients with steroid-resistant acute graft-versus-host disease…
- Trial name
- NCT02241018
- Testing
- CD25 monoclonal antibody, calcineurin inhibitors, MSCs
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Graft Versus Host Disease
Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease
The purpose of this research is to test the safety and efficacy of brentuximab vedotin in patients with acute skin graft-versus-host disease (GVHD)
- Trial name
- NCT01616680
- Testing
- brentuximab vedotin, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Hematopoietic and Lymphoid Cell Neoplasm
Fecal Microbiota Transplantation for Steroid Resistant/Dependent Acute GI GVHD
The purpose of this study is to evaluate the efficacy and safety of fecal microbiome transplantation in patients with steroid resistant/dependent acute gastrointestinal graft-versus-host disease (GVHD).
- Trial name
- FEMITGIGVHD (NCT03812705)
- Testing
- fecal microbiome transplantation
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Graft Vs Host Disease
Safety Study of Preimplantation Factor (PIF-1) to Treat Acute Steroid-Resistant Graft-Versus-Host Disease (GVHD)
The primary goal of this study is to determine the safety and tolerability of a novel peptide - preimplantation factor (PIF-1) - in patients who develop acute steroid-resistant graft-versus-host disease (GVHD) after matched bone…
- Trial name
- PIF1GVHD (NCT00517907)
- Testing
- Preimplantation factor (PIF-1)
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- Hadassah Medical Organization
Graft-versus-host Disease, Poor Graft Function
Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function
The present project aims at investigating the role of MSC for the treatment of patients with Part 1: Steroid-refractory grade II-IV acute GVHD.
- Conditions
- Graft-versus-host Disease, Poor Graft Function, Low Donor T-cell Chimerism
- Trial name
- NCT00603330
- Testing
- Mesenchymal stem cells
- Where
- 12 sites in Belgium, Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Liege
Steroid Resistant Acute Graft Versus Host Disease
Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease
Leukotac (inolimomab) is not approved yet for marketing in any region. In the absence of medical options and based on the safety and efficacy data obtained during the clinical development program (in a phase III (INO-107) and in…
- Trial name
- NCT05047328
- Testing
- inolimomab
- Where
- France
- Sponsor
- ElsaLys Biotech
Graft Vs Host Disease
Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease
Trial evaluating the improvement in survival at 180 days of two therapies (Atgam versus ABX-CBL, a monoclonal antibody) in patients with acute graft versus host disease that does not respond to steroid therapy.
- Trial name
- NCT00035880
- Testing
- ABX-CBL
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Abgenix
Steroid-resistant Severe aGVHD
MSC for Severe aGVHD
Steroid-resistant acute graft-versus-host disease (aGVHD) is one of the most severe complications in the setting of allogeneic hematopoietic stem cell transplantation (HSCT), which cannot be significant benefit from the…
- Trial name
- NCT03631589
- Testing
- MSCs
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fujian Medical University
Graft-versus-host-disease
Treatment of Steroid Resistant GVHD by Infusion MSC
For numerous malignant diseases allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy. One of the major complications is the occurrence of acute graft-versus-host-disease (aGVHD).
- Trial name
- MSCforGVHD (NCT00827398)
- Testing
- MSC (hPPL)
- Where
- 2 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- N.M. Wulffraat
Pediatric Mmune Thrombocytopenic Purpura
Steroid Resistance in Pediatric Immune Thrombocytopenic Purpura
To Predicting steroid resistance on children newly diagnosed with immune thrombocytopenic purpura
- Trial name
- ITP (NCT06601543)
- Volunteers
- 102 people
- Sponsor
- Assiut University
Graft vs Host Disease
Mesenchymal Stem Cells as First Treatment Line for Resistant Acute Graft Versus Host Disease
Steroids are still the first line treatment for established severe acute-graft-versus-host-disease (aGVHD), with a response rate of 30-50%, and there is no established and effective therapy for severe steroid-refractory (aGVHD).
- Trial name
- NCT02770430
- Testing
- mesenchymal stem cells, conventional treatment
- Where
- Brazil
- Volunteers
- 90 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Steroid Refractory GVHD
Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD
A Phase 3, Multicenter, open label, study to Evaluate the EFficacy and SaFEty of Leukotac® (inolimomab) in pediatric patients with steroid resistant acute Graft versus Host Disease (SR-aGvHD)
- Trial name
- EiFFEL (NCT04289103)
- Testing
- Inolimomab (Leukotac)
- Volunteers
- 65 people
- Sponsor
- ElsaLys Biotech